NCT01894672View on ClinicalTrials.gov

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

March 17, 2016

Study Completion Date

March 17, 2016

Conditions
Melanoma
Interventions
DRUG

LGX818

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

10591

Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow

11570

Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre

11725

Memorial Sloan Kettering Cancer Center at Commack, Commack

Unknown

Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge

Sponsors

Collaborators (1)

Array BioPharma
All Listed Sponsors
collaborator

Array BioPharma

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER